background image
Our most advanced proprietary clinical programs include:
Proprietary Program
Indication
Clinical Status
1. ARRY-520
Kinesin spindle protein, or KSP, inhibitor for
Phase 2
multiple myeloma
2. ARRY-614
p38/Tie2 dual inhibitor for myelodysplastic
Phase 1
syndromes, or MDS
3. ARRY-797
p38 inhibitor for pain
Phase 2
4. ARRY-502
CRTh2 antagonist for asthma
Phase 2
In addition, we have 10 partner-funded clinical programs including two MEK inhibitors in Phase 2 clinical
trials: selumetinib with AstraZeneca and MEK162 with Novartis:
Drug Candidate
Indication
Partner
Clinical Status
1. Selumetinib
MEK inhibitor for cancer
AstraZeneca, PLC
Phase 2
2. MEK162
MEK inhibitor for cancer
Novartis International
Phase 2
Pharmaceutical Ltd.
3. Danoprevir
Hepatitis C virus protease
InterMune (now
Phase 2
inhibitor
owned by Roche
Holding AG)
4. AMG 151
Glucokinase activator for Type 2
Amgen Inc.
Phase 2
diabetes
5. ARRY-543/ASLAN001
HER2/EGFR inhibitor for gastric
ASLAN
Phase 2
cancer
Pharmaceuticals
Pte Ltd.
6. GDC-0068
AKT inhibitor for cancer
Genentech Inc.
Phase 2
7. LY2603618
Chk-1 inhibitor for cancer
Eli Lilly and
Phase 2
Company
8. GDC-0575 and GDC-0425
Chk-1 inhibitors for cancer
Genentech Inc.
Phase 1b
9. ARRY-382
cFMS inhibitor for cancer
Celgene Corporation
Phase 1
10. VTX-2337
Toll-like receptor for cancer
VentiRx
Phase 1b
Pharmaceuticals, Inc.
We also have a portfolio of proprietary and partnered drug discovery programs generated by our internal
discovery efforts. Our internal drug discovery programs include inhibitors that target Trk receptors for the
60
treatment of pain and G-protein-coupled receptor 119 for the treatment of diabetes. We may choose to
out-license select promising candidates through research partnerships.
Any information we report about the development plans or the progress or results of clinical trials or other
development activities of our partners is based on information that is publicly disclosed.
Our significant collaborators include:
Amgen We entered into a worldwide strategic collaboration with Amgen in December 2009 to
develop and commercialize our glucokinase activator, AMG 151, which is currently in Phase 2
development for Type 2 diabetes, and to discover potential back-up compounds for AMG 151.
ASLAN Pharmaceuticals We entered into a collaboration and license agreement with ASLAN
Pharmaceuticals in July 2011 to develop Array's HER2 / EGFR inhibitor, ASLAN001, which is
currently in a Phase 2 clinical trial in patients with gastric cancer.
AstraZeneca In December 2003, we entered into a collaboration and license agreement with
AstraZeneca under which AstraZeneca received a license to three of our MEK inhibitors for
cancer, including selumetinib, which is currently in multiple Phase 2 clinical trials.
Celgene We entered into a worldwide strategic collaboration agreement with Celgene in
September 2007 focused on the discovery, development and commercialization of novel
therapeutics in cancer and inflammation. The most advanced drug is ARRY-382, a cFMS inhibitor
for cancer, which is currently in a Phase 1 clinical trial.
Genentech We entered into a worldwide strategic collaboration agreement with Genentech in
January 2003, which was expanded in 2005, 2008, and 2009, and is focused on the discovery,
development and commercialization of novel therapeutics. The most advanced drug is GDC-0068,
an AKT inhibitor for cancer, which is currently in a Phase 2 trial. The other programs under this
collaboration are in preclinical development. In August 2011, we entered into an oncology
partnership with Genentech for the development of each company's small-molecule Checkpoint
kinase 1 (ChK-1) program. The programs include Genentech's compound GDC-0425 (RG7602)
and Array's compound, GDC-0575, both of which are in Phase 1 clinical trials in patients with
cancer.
Novartis We entered into a worldwide strategic collaboration with Novartis in April 2010 to
develop and commercialize our MEK inhibitor, MEK162, and other MEK inhibitors identified in the
agreement. MEK162 is currently in numerous Phase 1b and Phase 2 clinical trials in patients with
cancer.
InterMune (program acquired by Roche) We entered into a collaboration with InterMune in 2002,
which resulted in the joint discovery of danoprevir, a novel small molecule inhibitor of the Hepatitis
C Virus NS3/4A protease. Roche Holding AG acquired danoprevir from InterMune in 2010.
Danoprevir is currently in Phase 2b clinical trials.
Business Development and Collaborator Concentrations
We currently license or partner certain of our compounds and/or programs and enter into collaborations
directly with pharmaceutical and biotechnology companies through opportunities identified by our
business development group, senior management, scientists and customer referrals.
61